The Four Certificate Pathways for Medical Devices in Myanmar

1. Key takeaways

The certificate system for medical devices in Myanmar comprises at most four types: the Import Recommendation (used for import), the Import Notification (used for import), the Manufacturing License (for local manufacturers) and the Product Registration (for local products). The official source of this classification is the announcement made by the Myanmar Food and Drug Administration at the 7th ASEAN Medical Device Committee (AMDC) meeting.

• These four certificate types are divided along two crossing axes: import versus local production, and recommendation versus notification.
• The typical situation of a foreign manufacturer is the import pathway, so the company must clarify whether its product falls under the recommendation or the notification; this determination should be made upfront at the project initiation stage.
• Apart from 126 newly exempted devices, all other devices require the corresponding certificate.
• Import control follows a three-step architecture: pre-market, post-market, and cooperation with related departments.
• The Myanmar FDA has accepted device registration applications in the form of Import Notifications and Import Recommendations since 2000.
• The certificate announcement was made public in December 2018, which means the four-type framework is younger than the underlying import practice it codifies, and the framework should be read together with the pre-2018 practice records.
• For a foreign manufacturer, the local production certificates, the Manufacturing License and the Product Registration, are generally not reachable, because they are addressed to local manufacturers and local products; the realistic planning space therefore lies in the two import documents and the exemption list.

2. Legal basis

The table below reproduces the certificate framework as officially announced, together with the exemption and architecture details that determine which certificate, if any, a given product requires.

3. Expert insights

Insight 1: the formulation of at most four types shows that not every product needs all certificates. Which type is required depends on whether the product is imported or locally produced, and whether it falls within the exemption list. Companies must determine this case by case, and the determination should be documented in writing before the dossier is built.

Insight 2: the Import Recommendation and the Import Notification are two different documents for import. They are listed side by side in the official announcement, which shows that their functions differ. When preparing customs clearance documents, companies must confirm which of the two their product requires, and the confirmation should be obtained in writing through the local authorised representative so that the clearance agent and the registrant work from the same determination.

Insight 3: the three-step architecture links pre-market and post-market into one system. The official position is that import control comprises three steps: pre-market, post-market and cross-departmental cooperation. This signals that companies must not treat registration as the end point; post-market obligations are equally part of access management. In practical terms, a product whose registration is complete but whose post-market reporting channels are not set up is not fully compliant under this architecture, and the cooperation step means other government departments may become involved in import matters beyond the FDA itself.

Insight 4: the list of 126 exempted devices is the first sieve for determining whether a certificate is needed. Checking the exemption list before starting registration can directly save unnecessary registration investment. The list was expanded at the 7th AMDC meeting. Whether a product falls within the current list is a practical estimate pending verification against the latest FDA publication.

Insight 5: the system has run since 2000 and has formed a stable practice. Although a dedicated law is lacking, the dual-track practice of Import Notifications and Import Recommendations has more than twenty years of history, and the review interpretations of the competent authority show continuity. This continuity is a practical advantage for foreign manufacturers, because it makes past determinations a meaningful reference, although each new determination remains subject to the current interpretation of the FDA as a practical estimate pending verification.

4. Practical recommendations

• Check the exemption list first, then start registration. Determine whether the product belongs to the 126 exempted devices.
• Distinguish the import pathway from the local production pathway. The certificate types and documentary requirements differ between the two.
• Clarify the applicable situations of the Import Recommendation and the Import Notification. Confirm this at the project initiation stage, not before shipment.
• Include post-market obligations in the access plan. Arrange them under the three-step architecture in an integrated way.
• Retain the written basis for the certificate type determination. This facilitates later change and renewal connections.

5. Verification checklist

• □ Confirmed that Myanmar device certificates number at most four types
• □ Confirmed the applicable objects of the four certificate types (import or local production)
• □ Reviewed the list of 126 exempted devices
• □ Confirmed the certificate pathway for the products
• □ Clarified the applicable situations of the Import Recommendation or Import Notification at the project initiation stage
• □ Included post-market obligations in the access plan
• □ Retained the written basis for the certificate type determination

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com